Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply” and “GSK insider trading Form 4 transactions.”
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK plc reported a routine share buyback. Acting through BNP Paribas SA, the company purchased 310,000 ordinary shares on 16 October 2025 at prices between 1,621.50p and 1,637.00p per share, with a volume-weighted average price of 1,629.84p. The shares will be held as Treasury shares under the existing non-discretionary buyback agreement announced on 30 September 2025. Since that date, GSK has purchased 4,229,500 shares.
Following this transaction, GSK holds 251,694,344 shares in treasury and has 4,063,719,485 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,063,719,485, and the percentage of voting rights attributable to treasury shares is 6.19%.
GSK plc reported insider acquisitions of American Depositary Shares through automatic dividend reinvestment. On October 14, 2025, ADSs were acquired at $43.9461 per ADS on the New York Stock Exchange, reflecting the reinvestment of dividends paid on October 9, 2025.
Hal Barron acquired 3,186.736 ADSs. James Ford acquired 321.543 ADSs. Shobie Ramakrishnan acquired 387.334 ADSs. Each entry is recorded as a single transaction, with the instrument identified as GSK ADSs (ISIN: US37733W2044).
These transactions are routine dividend reinvestments by directors and senior management and do not reflect an open‑market discretionary purchase program.
GSK plc repurchased 405,500 ordinary shares on 15 October 2025 as part of its existing buyback programme, executed by BNP Paribas SA under a non-discretionary agreement announced on 30 September 2025. The shares were bought at a volume-weighted average price of 1,617.97p, within a price range of 1,608.00p to 1,633.00p, and will be held as treasury shares.
Since 30 September 2025, the company has purchased 3,919,500 ordinary shares. Following this transaction, GSK holds 251,384,344 ordinary shares in treasury and has 4,064,029,485 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,064,029,485, and the percentage of voting rights attributable to treasury shares is 6.19%.
GSK plc filed a Form 6-K reporting transaction notifications. The filing lists share transactions with an ISIN GB00BN7SWP63 at a price of 3.0300 and multiple entries for ISIN US37733W2044 at a price of $40.7387. The document repeats the US ISIN and price across several lines and provides an aggregated section header, but it does not disclose volumes, the parties to the transactions, transaction types, or any explanatory context. The filing is dated September 22, 2025.
GSK plc reported share repurchases under its ongoing buyback programme. On 18 September 2025 the Company, through Merrill Lynch International, purchased 15,858 ordinary shares at prices between 1,471.00p and 1,480.00p, with an aggregated per-share reference of 1,476.54p. Since the non-discretionary agreement began on 4 June 2025 the Company has purchased 29,330,461 ordinary shares. After these transactions GSK holds 247,464,844 shares in treasury and has 4,067,938,124 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,067,938,124 and the percentage of voting rights attributable to treasury shares is stated as 6.08%.
GSK plc repurchased 209,886 ordinary shares on 17 September 2025 through Merrill Lynch International under its ongoing buyback programme, at prices ranging from 1,461.50p to 1,478.50p, with an average price reported as 1,471.87p. The purchased shares will be held as treasury shares.
Since the non-discretionary agreement with the broker on 4 June 2025 the company has acquired 29,314,603 ordinary shares. After this trade GSK holds 247,448,986 shares in treasury and has 4,067,953,982 ordinary shares in issue (excluding treasury), representing total voting rights of 4,067,953,982 and 6.08% of voting rights attributable to treasury shares.
GSK announced a five-year, $30 billion investment plan in the United States to expand research, development and supply chain infrastructure. The announcement includes a $1.2 billion package for advanced manufacturing, AI and digital capabilities that will create hundreds of highly skilled U.S. jobs and build a next-generation biologics "flex" factory at Upper Merion, Pennsylvania, with construction planned to begin in 2026. GSK said the wider $30 billion commitment will fund capital projects across its U.S. supply chain, boost R&D drug discovery and clinical trial activity, and increase the U.S. share of its global clinical studies. The filing notes GSK has added roughly $2 billion in U.S. manufacturing investments over the last 12 months, including an $800 million Marietta, Pennsylvania facility started in October 2024, and that its global supply chain delivered 1.7 billion packs of medicines and over 400 million vaccine doses last year.
GSK plc announced that, acting through Merrill Lynch International, it repurchased 210,377 ordinary shares on 16 September 2025 at prices between 1,462.00p and 1,478.00p per share, with an aggregated average shown as 1,468.98p. These shares will be held as treasury stock as part of the buyback programme announced 4 June 2025. Since 4 June 2025 the company has repurchased 29,104,717 ordinary shares. After this trade GSK holds 247,239,100 shares in treasury and has 4,068,163,868 ordinary shares in issue (excluding treasury), giving total voting rights of 4,068,163,868 and treasury-held voting rights of 6.08%.
GSK plc reported a purchase of ordinary shares under its ongoing buyback programme. On 15 September 2025 the Company, acting through Merrill Lynch International, purchased 253,331 ordinary shares at prices ranging up to 1,505.50p, with an aggregated weighted lowest/highest/average price line reported as 1,476.00p / 1,505.50p / 1,482.92p on that date. Since the non-discretionary agreement with the Broker dated 4 June 2025, GSK has purchased 28,894,340 ordinary shares in total. Following the 15 September purchase the Company holds 247,028,723 shares in treasury and has 4,068,374,245 ordinary shares in issue (excluding treasury), giving total voting rights of 4,068,374,245 and treasury shares representing 6.07% of voting rights.
GSK plc reports on 12 September 2025 that, acting through Merrill Lynch International, it purchased 203,447 ordinary shares at an average price of 1,512.69p per share as part of its ongoing buyback programme under a non-discretionary broker agreement dated 4 June 2025. Since 4 June 2025 the company has repurchased 28,641,009 ordinary shares. Following the transaction GSK will hold 246,775,392 shares in treasury and will have 4,068,627,576 ordinary shares in issue (excluding treasury). Total voting rights are 4,068,627,576 and treasury shares represent 6.07% of voting rights.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
